## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.4% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($795.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Does McKesson Still Offer Value After Its Big 2025 Run and Cash Flow Outlook?**
- Source: Simply Wall Street | 20251224T040842 | Bullish | Relevance: 100%
- McKesson's stock has seen significant growth in 2025, raising questions about its current valuation. Despite a recent slight pullback, the company is viewed as critical infrastructure in US healthcare. A Discounted Cash Flow analysis suggests McKesson is undervalued by 41.0%, while its Price to Earnings ratio also indicates undervaluation when considering its specific growth outlook and risk profile.

**2. 3 Big Reasons to Love McKesson (MCK)**
- Source: FinancialContent | 20251223T230500 | Bullish | Relevance: 100%
- McKesson (MCK) is highlighted as a high-quality business due to its strong long-term revenue growth (10.6% CAGR over five years), significant economies of scale with $387.1 billion in revenue, and impressive long-term EPS growth of 18.3% CAGR. These factors indicate its offerings resonate with customers, it possesses strong negotiating leverage, and it has become increasingly profitable. The article encourages readers to consult a full research report to determine if it's currently a buy.

**3. Mckesson Corporation Announces Third Quarter Fiscal 2026 Earnings Release Date**
- Source: Business Wire | 20251222T130844 | Neutral | Relevance: 100%
- McKesson Corporation will release its third-quarter fiscal 2026 financial results after market close on Wednesday, February 4, 2026. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results, which will be available on its Investor Relations website. McKesson is a diversified healthcare services leader committed to improving health outcomes.

**4. McKesson Corporation: FY26 Earnings Visibility Underpins Buy Case (NYSE:MCK)**
- Source: Seeking Alpha | 20251222T232643 | Bullish | Relevance: 100%
- McKesson Corporation is undervalued despite strong revenue growth, margin expansion, and capital returns, leading to a "Buy" rating with a $920 target price, reflecting a 13.5% upside. The company's strategy involves boosting margins through high-margin oncology and multispecialty growth while divesting lower-margin medical-surgical solutions. Strong Q2 results, low leverage, and planned aggressive share buybacks further support the investment thesis.

**5. McKesson stock price target maintained at $1,000 by TD Cowen on growth outlook**
- Source: Investing.com | 20251222T200842 | Somewhat-Bearish | Relevance: 100%
- TD Cowen maintained its Buy rating and $1,000 price target for McKesson (NYSE:MCK), citing strong growth prospects driven by demographic trends, pharmaceutical innovation, and investments in AI and specialty drugs. This follows recent meetings with management and positive Q2 2026 earnings, where McKesson surpassed EPS forecasts. Other firms like Leerink Partners and Evercore ISI have also raised their price targets recently, reflecting confidence in the company's performance and outlook.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.98 indicates undervaluation relative to growth. Balance sheet: $2.3B free cash flow. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $102.8B |
| Beta | 0.38 |
| 52W Range | $565.75 - $895.58 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.98 |
| Forward P/E | 18.9 |
| Current P/E | 21.4 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.4% to -0.4% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.4pp (needs >3.0% for momentum thesis). RSI neutral at 52. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.38% (CS: 64) | Neutral |
| RSI_14 | 51.7 | Neutral |
| MACD Histogram | 0.45 | Bullish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 1.125x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $826.43
- **Stop Loss:** $795.55 (3.7% risk)
- **Target:** $857.31 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 38
- **Position Value:** $31,404.34
- **Portfolio %:** 31.40%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*